Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug
20/05/2025 01:31
May 19 (Reuters) - Pfizer PFE.N has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc 1530.HK for the development, manufacturing and commercialization of a drug undergoing trials for treatment of certain types of cancer and tumours, the U.S. drugmaker said on Monday. (Reporting by Kanjyik Ghosh; Editing by Alan Barona) ((Kanjyik.Ghosh@thomsonreuters.com))